tirzepatide cancer BREAKING NEWS 🚨 A new study from the University of Michigan found that SHRINKS BREAST TUMORS IN MICE. For women 40–55, this matters. Weight gain and breast cancer risk both Is it safe for a

Observational studies Most of the early observational evidence from case-control and nested case-control studies suggested either null or inverse associations between selenium exposure and risk of site-specific cancers (67)

After 46 weeks of treatment: 0.6 mg dose: 6.2% mean body weight reduction 2.4 mg dose: 12.5% mean body weight reduction 3.6 mg dose: 13.2% mean body weight reduction 4.8 mg dose: 14.9% mean body weight reduction (all randomized) 4.8 mg dose: 18.7% mean body weight reduction (completers only) Placebo: 2.8% mean body weight reduction Among completers at the 4.8 mg dose, 68.8% achieved at least 10% weight loss, 67% achieved at least 15%, and 40% achieved at least 20% weight loss

Por que priorizar um produto para emagrecimento em detrimento de medicamentos indispensveis para salvar vidas ou aliviar o sofrimento de pacientes e de suas famlias?, questiona o presidente executivo do Sindusfarma, Nelson Mussolini

Bar chart showing total T3 and total T4 in studied groups